144 articles in this topic
Go beyond the basics and explore the molecular machinery that keeps your nuclear envelope intact — and the precise failure modes that drive cellular aging when it breaks down.
Discover how a tiny scaffolding inside your cells helps keep your DNA safe — and what happens when it starts to break down as you age.
A clinical account of the nutrient-sensing trade-off — what actually induces cellular clean-up in humans rather than in mice, why muscle wins the argument in an older patient, and where the rapamycin and metformin evidence genuinely stops.
What a senescent cell is, how a small population drives systemic inflammation, and an honest account of senolytic human data — early-phase, mechanistic, and short of any outcome a patient cares about.
A deep mechanistic dive into the signaling cascades, epigenetic reprogramming, and translational science behind parabiosis — from GDF11 controversies to clinical plasma trials.
Go beyond the basics of parabiosis to explore the specific proteins, exosomes, and signaling pathways that make young blood rejuvenating — and old blood damaging.
Discover how scientists joined the circulatory systems of young and old mice — and what it taught us about the surprising power of bloodstream factors to reverse signs of aging.
A clinical guide to protein and metabolite measurement — why these layers report present state rather than inherited risk, what broad panels can and cannot support, and how to judge an organ-age or metabolomic result you did not order.
A deep mechanistic investigation into how rapamycin and next-generation rapalogs modulate aging pathways — from allosteric binding kinetics to clinical trial design and emerging bi-steric inhibitors.
A clinical guide to interpreting biological-age and pace-of-aging results: what the epigenome is, what each generation of clock was trained to predict, why repeat testing of the same sample can differ by years, and how to counsel a patient who wants to buy one.
Go beyond the basics — explore the molecular machinery linking mTOR inhibition to lifespan extension, and what the latest research tells us about rapamycin's real-world potential.
The fourth-tier hallmarks — regenerative decline, altered tissue signaling, inflammaging and gut dysbiosis — are the ones that actually walk into clinic. How to measure them with a dynamometer, a hallway and a short lab panel, and which single prescription moves several at once.
